Since the PD-1:PD-L1 axis already has FDA-approved drugs (e.g., nivolumab and avelumab) capable of impacting beneficially on survival in RCC patients, we chose to focus on targeting TGF-β1. The gene discussed is TGFB1; the disease is renal cell carcinoma.